more than 3% POX positivity on their blasts were studied. The
Introduction after myelodysplastic syndrome were excluded.
CD4 was originally identified as a T cell differentiation antigen, which characterizes helper/inducer type T cells. 1 It is Immunophenotyping now known that CD4 is also expressed on the surface of monocytes/macrophages, 2, 3 eosinophils, 4 and megakaryoMononuclear cells (MNC) were separated from heparinized cytes. 5 In addition, CD4 has recently been detected on hema-PB and BM samples by Ficoll-Hypaque centrifugation. More topoietic progenitor cells of mice and humans. [6] [7] [8] [9] Mouse than 95% of separated MNC consisted of leukemia cells mor-CD4 low Gr-1 low cells, when injected into lethally irradiated phologically in each case. Before immunostaining, MNC were mice, differentiated into T cell, B cell, and myelomonocyte treated with 5% heat-aggregated human AB serum to block lineages.
6 CD4 density on the surface of hematopoietic probinding due to receptors for IgG Fc portion (Fc␥R). CD11b genitor cells was approximately half of that of peripheral (recognized by OKM1), CD13 (by MCS2), CD15 (by LeuM1), blood (PB) monocytes and 5% of PB T lymphocytes. 8 CD4 CD33 (by My9), and CD34 (by HPCA-1) were tested as antigen expressed by bone marrow (BM) hematopoietic promyeloid cell markers. CD2 (by OKT11), CD5 (by Leu1), CD7 genitor cells appeared to be the same form expressed by (by TP40), CD3 (by Leu4), CD4 (by Leu3a), and CD8 (by Leu2) mature PB CD4 + cells. This was shown by immunoprecipitwere tested as T cell markers. CD19 (by Leu12), CD20 (by ation experiments, and CD4 mRNA identity was confirmed by Leu16), and CD22 (by Leu14) were tested as B cell markers. the reverse-transcription polymerase chain reaction. 8 CD10 and HLA-DR were examined with J5 and OKIa1, CD4 expression has been reported in a significant number respectively. Goat anti-mouse Ig fluorescein isothiocyanate of cases of AML cells. Several authors interpreted CD4 positiv-(GAM-FITC) was used as the second reagent. In some cases, ity in myeloid leukemia as an aberrant expression of a lymphstored cells were double stained using FITC-conjugated CD34 oid marker.
10,11 However, recent reports have suggested CD4 and phycoerythrine (PE)-conjugated CD4. Samples were expression in AML is consistent with the presence of CD4 on evaluated by flow cytometry (Cytoron; Ortho Diagnostic Sysnormal myeloid precursors and monocytes.
12-14 The purpose tems, Tokyo, Japan). At least 5000 cells were examined for each surface marker. Monoclonal antibodies, TP40 and MCS2 were kindly provided by Drs R Ueda (Nagoya City University, Nagoya, Japan) and E Tatsumi (Kobe University, Kobe, Japan), respectively. were referred to as high.
were from Ortho. Whole mouse Igs, IgG1 and IgG2 used as the controls were purchased from Chemicon (Temecula, 3 H-TdR uptake analysis and cell culture CA, USA).
T cells and adherent cells were eliminated from the mononuclear cell fraction to obtain the leukemic cell-enriched fracCytokine receptor expression tion. The leukemia cells were suspended in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf In 93 cases enrolled after January 1994, receptor expression of various cytokines was examined by monoclonal antibodies. serum (FCS), and adjusted to a concentration of 1 × 10 6 cells/ml. 50 l of the cell suspension and an equal volume Anti-interleukin-3 receptor ␣ (IL-3R␣, CD123) MoAb (N3A) was a kind gift from Dr T Kitamura (DNAX, Palo Alto, CA, of the medium containing a growth-stimulating factor were cultured in 96-well culture plates (U-bottom; Nunc, Roskilde, USA). Anti-c-kit (CD117) MoAb was purchased from Immunotech (Marseille, France), anti-granulocyte-macrophage colDenmark) for 48 h at 37°C in a fully humidified incubator containing 5% CO 2 . Cells suspended only in RPMI-1640 ony-stimulating factor receptor ␣ (GM-CSFR␣, CD116) from Genzyme (Cambridge, MA, USA), and anti-IL-6R␣ (CD126) medium supplemented with 10% FCS were tested as a control. 50 l of 2 Ci/ml 3 H-TdR (Amersham, Buckinghamshire, from Serotec (Oxford, UK). Granulocyte colony-stimulating factor (G-CSFR, CD114) expression was detected by PE-lab-UK) was then added to the cell culture. After 6-h incubation, the cells were harvested on glass-fiber filters, and 3 H-TdR eled G-CSF (R&D Systems, Minneapolis, MN, USA).
Antigen or receptor expression was estimated by the relative incorporation was measured in a liquid scintillation counter. 
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CD11b neg 2.6 ± 8.6
c-kit neg 7.8 ± 11.5 
Karyotype analysis Clinical features
Age at onset and sex distribution were compared among the three categories of CD4 expression. Hepatomegaly, splenoKaryotype analysis was performed on BM cells, as described previously. 17 The chromosomes were classified according to megaly, central nervous system (CNS) involvement, skin involvement, and disseminated intravascular coagulation the International System for Human Cytogenetic Nomenclature (ISCN) (1985) .
(DIC) at presentation were examined. Complete remission Table 4 Responsiveness to cytokines in relation to CD4 expression (CR) rate after the induction therapy was also examined. OverResults all survival was compared between CD4 + and CD4 − cases. Table 3 . ckit was ubiquitously expressed. Expression of IL-3R␣, GMincreased in parallel to that of CD4. Intensity of CD13 9  25  5  8  5  2  8  15  0  Total  36  52  53  25  20  14  16  21  3  Normal karyotype  44  40  8  31  19  2  25  14  2  FAB  M1  12  34  11  7  10  5  2  8  1  M2  21  41  52  22  9  6  11  7  4  M3  38  13  0  22  3  0  3  0  0  M4  10  17  2  8  19  4  11  11  1  M5  4  8  1  13  5  0  16 ). Although CD4 high CD34 high cases were very rare (n = 6), they differ from CD34 high cases with low or negaare shown in Table 4 . Responses to IL-3, GM-CSF and G-CSF were highest in CD4 neg cases and lowest in CD4 high cases, tive CD4 expression because of a slightly higher expression of CD33 and CD11b, frequent chromosome 7 abnormalities although the difference was statistically significant only for IL-3. Response to IL-6 of CD4 neg and CD4 high cases were almost (three of five cases examined), and relatively high age (58.3 years). equal and the mean 3 H-TdR value of CD4 low cases was less than that of control culture without any cytokine.
CD4 expression in AML cells

Clinical pictures of CD4
− and CD4 + AML patients Chromosomal abnormalities in relation to CD4 expression Table 7 shows the clinical aspects of AML in relation to CD4 expression. Patients with CD4 + AML were older. There were no difference in sex distribution between each category of Chromosomal analysis of AML cells was successfully done in 415 cases (Table 5 ). CD4 was expressed in 40.4% of AML CD4 expression. At presentation, there was no statistical difference in the incidence of hepatomegaly, splenomegaly, CNS cases having chromosome abnormalities, while 50.3% of AML cases with a normal karyotype were CD4-positive. CD4 involvement, skin involvement or DIC between CD4 neg , CD4 low and CD4 high cases. In this study, 366 patients were was frequently expressed in AML cells with 11q23 chromosome abnormalities (93.7%), and 50% of cases with this karytreated with BHAC-DMP chemotherapy (behenoyl cytosine arabinoside (BH-AC), daunorubicin (DNR), 6-mercaptopurine otype were CD4 high . CD4 expression was also frequent in cases with inv(16) (70.0%); 60% of these were CD4 low . 34.0% (6-MP), and prednisolone (PDN)) as induction therapy, and with some minor variations in consolidation and maintenance of t(15;17) cases were CD4-positive, most of which were CD4 low . Two cases of t(9;22) AML showed weak expression therapies. CR rate for this regimen was not statistically different between the three subgroups of CD4 expression. Figure 1 ). Phenotypes, karyotypes and FAB classification of AML cases in relation to CD4 and CD34 expression although a recent paper, 14 in which CD4 was positive in a remarkably high percentage of AML cases (68%), found that are shown in Table 6 . Regardless of the intensity of CD4 expression, CD34 high cases showed the lowest expression of CD4 did not distinguish myeloid from monocytic leukemia: CD4 was positive in 60% of M1, M2 and M3 cases, and 73% myelomonocytic differentiation antigens (CD33 and CD11b) and the highest HLA-DR expression. In addition, most of the of M4 and M5 cases. In the present study, CD4 
